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Abstract
As part of a larger literature study on transgenic animals in mutagenicity testing, test results from
the transgenic mutagenicity assays (lacI model; commercially available as the Big Blue® mouse, and
the lacZ model; commercially available as the Muta™Mouse), were compared with the results on
the same substances in the more traditional mouse bone marrow micronucleus test. 39 substances
were found which had been tested in the micronucleus assay and in the above transgenic mouse
systems. Although, the transgenic animal mutation assay is not directly comparable with the
micronucleus test, because different genetic endpoints are examined: chromosome aberration
versus gene mutation, the results for the majority of substances were in agreement. Both test
systems, the transgenic mouse assay and the mouse bone marrow micronucleus test, have
advantages and they complement each other. However, the transgenic animal assay has some
distinct advantages over the micronucleus test: it is not restricted to one target organ and detects
systemic as well as local mutagenic effects.
Background
This and the following presentation are part of a project
for the International Programme on Chemical Safety
(IPCS) evaluating the possible use of transgenic animal
mutagenicity assays in chemical toxicity testing and mech-
anistic research. It was decided to compare the results
obtained from those transgenic mutagenicity test systems
where considerable data was available, with other in vivo
genotoxicity tests: in the first article (Part 1) with the
mouse bone marrow micronucleus test and in the second
(Part II) with the mouse spot test.
The mouse bone marrow micronucleus test is one of sev-
eral available in vivo mammalian test system for the detec-
tion of chromosomal aberrations [1-5]. A documentation
of the test procedure and evaluation of results is given in
the OECD guideline 474 [6]. This test is routinely used
with a widespread acceptance in industry and authorities.
Mutagenicity assays using transgenic animals have been
developed in particular the lacI model [7] (commercially
available as the Big Blue® mouse), and the lacZ model [8]
(commercially available as the Muta™Mouse). In this arti-
cle, available data on the results of mouse bone marrow
micronucleus test were compared with results from these
two transgenic mouse assays for 39 substances. The
advantages and disadvantages of the test systems are dis-
cussed. Recently, further transgenic rodent mutation
assays have been developed, however, the data base is not
sufficient for comparison with other test systems.
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The mouse bone marrow micronucleus test: principles and 
procedure
Micronuclei are chromatin-containing bodies in the cyto-
plasm arising from acentric chromosome fragments or
from whole chromosomes that were not incorporated in
the daughter nuclei during the last stages of mitosis. Chro-
mosome fragments are associated with the clastogenic
(chromosome breakage) activity of the test substance
whereas the presence of a whole chromosome is indica-
tive of an adverse effect of the test substance on the mitotic
spindle apparatus (aneugenic effects). The difference in
size of the micronucleus is therefore an indicator for clas-
togenicity (small micronucleus) or aneugenicity (large
micronucleus). However, the size of the micronucleus is
an inaccurate measure. Micronuclei can be distinguished
by further criteria, for example by identification of the
presence of a kinetochore or centromeric DNA, indicating
aneugenic activity. Overall, an increase in micronuclei is
an indirect measure of induced structural or numerical
chromosome aberrations [1,2].
In the micronucleus test according to the OECD guideline
474, erythroblasts in the bone marrow of mice (or rats)
are used as target cells. When a bone marrow erythroblast
develops into a polychromatic erythrocyte, the main
nucleus is extruded. Any micronucleus that has been
formed may remain in the otherwise anucleated cyto-
plasm and can easily been detected. An increase in the fre-
quency of micronucleated polychromatic erythrocytes in
treated animals is an indication of induced chromosome
damage [6].
In the last three decades, toxicologists have often used the
mouse bone marrow micronucleus test because 1) it is
part of the regulatory toxicology in the admission proce-
dure for chemicals and drugs and 2) it has advantages in
speed, simplicity, and cost effectiveness in comparison to
other in vivo systems for testing chromosomal aberrations
(e.g. the cytogenetic test).
Transgenic mouse models
Transgenic mutation test systems contain a foreign gene
construct having two essential parts: the transgene con-
taining the target gene that serves as target for mutations,
and a shuttle vector for recovering the target gene DNA
from the tissue of the transgenic animal. The transgene is
constructed using recombinant DNA technologies.
LacI transgenic mouse model (Big Blue® mouse)
The proprietary mouse of the Big Blue® mutagenesis assay
system contains about 30–40 copies of a lambda LIZα
shuttle phage vector integrated into its genome at a single
locus on chromosome 4. The target site for mutagenesis is
the lacI gene [7].
The test compound is administered to the mouse either as
a single or repeated dose. After the post treatment period
for manifestation of the DNA lesions, the tissue of interest
is isolated and the DNA extracted. A proprietary lambda
DNA packaging extract automatically excises the lambda
vector target and packages it into a lambda phage head
and the phage is transfected to bacteria. These bacteria are
plated on agar indicator plates containing the chromoge-
nic substance (X-gal). The phage transfected bacteria with
mutations in the lacI gene form blue plaques, whereas
bacteria with a nonmutated lacI form colourless plaques.
The ratio between blue and white plaques is a measure of
the mutagenicity. [7,9].
LacZ transgenic mouse model (Muta™Mouse)
The lambda-gt10-lacZ shuttle vector for the lacZ mouse
model contains the entire lacZ target gene [8]. The com-
mercially available lacZ mouse model contains about 80
copies of the shuttle vector at chromosome 3.
As above, the test compound is administered to the
mouse, the genomic DNA is isolated from the tissue of
interest, and the lambda genomes are excised by and
packed with a bacteriophage packaging extract. The result-
ing phage particles are then plated on a lacZ- E. coli strain
(for transfection) in the presence of the chromogenic sub-
stance (X-gal) as indicator. The plaques containing an
intact lacZ are β-galactosidase active and are blue, whereas
plaques containing mutated lacZ will be white/colourless.
In this original model the ratio between colourless and
blue plaques is a measure of the mutagenicity. Due to
optical difficulties in the evaluation of plaques, this sys-
tem has been improved using a selection assay in lieu of
colour screening whereby only mutant particles form
plaques [10]. The number of plaques under non-selective
conditions is a measure for the total number of phage-
transfected bacteria (intact or mutant lacZ gene). The ratio
between the number of plaques produced under selective
conditions versus the number of plaques under non-selec-
tive conditions is a measure of the mutagenicity [9,10].
Methods
Data presented in this documentation are the results of an
extensive literature research. Concerning data on trans-
genic mouse assays only primary literature was used. Data
on the mouse bone marrow micronucleus assay were
extracted from reliable reviews on this item or from pri-
mary literature. For all other data informations from sec-
ondary literature or data compilation bases were used.
Results and Discussion
Comparison of data from the mouse bone marrow 
micronucleus test and transgenic mouse test
The authors are aware that a comparison of the transgenic
mouse assays with the mouse bone marrow micronucleusJournal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3
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test is limited by the fact that different genotoxic end-
points are studied in these two systems. In transgenic
mouse assays, point mutations and small insertions and
deletions are detected whereas in the mouse bone marrow
assay, chromosome breakage leading to light microscopi-
cally visible micronuclei resulting from chromosome frag-
ment or micronuclei originated from whole
chromosomes are investigated. However, both point
mutations and micronuclei may be induced by a single
agent, so some overlap of results is to be expected.
From the literature, 39 substances were identified with
data on the mouse bone marrow micronucleus test and
the Muta™mouse assay (n = 29) or the Big Blue® mouse
assay (n = 21) or both transgenic mutation assays (n =
11); see Additional file 1 for references. Agreement
between the Muta™mouse and the micronucleus test was
seen with 18 out of 29 substances, no agreement with 8
substances and in 3 cases the comparison is inconclusive
because of questionable results in the micronucleus assay.
With the Big Blue® mouse assay, the results obtained with
14 out of 21 substances agreed with results in the mouse
micronucleus test, but 6 showed no agreement and
another was inconclusive.
Most substances included in this comparison are also car-
cinogenic in long-term assays on mice. No data on carci-
nogenicity in mice are available for 4-
acetylaminofluorene and negative results were obtained
with bromomethane and 2,6-diaminotoluene.
Carcinogenic substances with positive results in the bone 
marrow micronucleus and transgenic gene mutation assays
Studies with Muta™mouse
The following 17 substances were gene mutagenic in at
least one of the examined organs in the Muta™mouse
assay, induced micronuclei in mouse bone marrow and
showed positive results in carcinogenicity studies on mice:
2-acetylaminofluorene, 4-aminobiphenyl,





nitrosodimethylamine, procarbazine, quinoline, and ure-
thane. Further studies on chromosome aberration in vitro
and in vivo (see Additional file 1) supported the results in
the micronucleus test, except data on 4-aminobiphenyl
(negative micronucleus test in rats) and quinoline (see
below).
Of the substances tested for mutagenic activity in bone
marrow in Muta™mice, 14 gave positive results, only 1,3-
butadiene, methylmethanesulfonate, and quinoline were
negative, indicating that other organs are more sensitive.
1,3-Butadiene is clearly clastogenic in other studies on
chromosome aberration in mice and induced gene muta-
tion in the bone marrow of Big Blue® mice (see Additional
file 1). Quinoline, however, gave inconclusive results in
other in vivo studies on clastogenic effects in bone marrow
of rats and mice.
Studies with Big Blue® mouse
12 substances showed gene mutagenic effects in at least
one of the examined organs in the Big Blue® mouse assay,
chromosome mutagenic effects in the mouse bone mar-
row micronucleus assay and induced carcinogenic effects
in long-term assays on mice,: 2-acetylaminofluorene, afla-
toxin B1, benzene, benzo(a)pyrene, 1,3-butadiene, cyclo-
phosphamide, 7,12-dimethylbenz(a)anthracene,
ethylene oxide, N-ethyl-N-nitrosourea, N-methyl-N-nitro-
sourea, N-nitrosodimethylamine, urethane. In the Big
Blue® mouse assay the target organ bone marrow revealed
also increased mutation frequencies induced by benzene,
1,3-butadiene, and 7,12-dimethylbenz(a)anthracene.
However, negative results in bone marrow were obtained
with cyclophosphamide, ethylene oxide, and N-
nitrosodimethylamine, indicating that other target organs
are more sensitive in the Big Blue® mouse assay. All of
these 12 substances induced also chromosome aberra-
tions in majority of further in vitro and in vivo studies.
Substances with carcinogenic effects in mice but no 
agreement between the transgenic mouse assay and the 
mouse bone marrow assay
Acrylamide
The inconclusive result in the bone marrow micronucleus
test [4] is contradictory to the Muta™mouse assay [21-23]
which shows mutagenic activity in the target organ bone
marrow but also contradictory to other in vivo tests on the
endpoint chromosome aberration including a cytogenetic
test on mice [4,19,21]. Micronuclei were detected in
spleen and testis of mice [4]. Overall, using other experi-
mental design the mouse bone marrow micronucleus
assay might give clearly positive results.
2-Amino-3-methylimidazo(4,5-f)quinoline (IQ)
IQ is mutagenic in the liver of the Muta™mouse [34] but
negative results were obtained in the mouse bone marrow
micronucleus test [2,35]. This negative result is supported
by a negative cytogenetic assay on mice. Inconclusive
results were obtained in in vitro studies on chromosome
aberrations but IQ induced micronuclei in rats (see Addi-
tional file 1). This discrepancy might be due to the possi-
bility that a) the liver but not the bone marrow of mice is
target organ (the liver but not the blood is target organ in
carcinogenicity [33]) or b) IQ is less clastogenic than gene
mutagenic in mice.Journal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3
Page 4 of 14
(page number not for citation purposes)
ortho-Anisidine
The target organ of carcinogenesis in mice (and humans)
is the bladder [36]. In the Big Blue® assay on mice muta-
genic activity was detected in the bladder but not in the
liver [37]. As expected, the mouse bone marrow micronu-
cleus test [4,36] gave negative results (also in rats; see
Additional file 1), because the bone marrow is presuma-
bly not a target organ of mutagenicity.
Asbestos crocidolite
Local carcinogenic effects were observed in carcinogenic-
ity studies, the lung is the target organ after inhalation
[38-40]. Mutagenic activity was detected in the lung of Big
Blue® mice after inhalation [41]. As expected, clearly no
systemic effects in the bone marrow could be observed in
the mouse micronucleus test [4].
2,4-Diaminotoluene
The main target organ in carcinogenicity is the liver (also
in rats) [81]. Positive results were reported in two Big
Blue®  mouse assays examining the liver [82-84]. The
mouse micronucleus test gave negative results [4], how-
ever, systemic effects in the bone marrow are not expected
from carcinogenicity studies. Results of other studies on
chromosome aberration in vivo are inconclusive (see
Additional file 1).
Hydrazine
This substance induced no mutagenic effects in lung, liver,
or bone marrow of the Muta™mouse which were target
organs in mouse carcinogenicity studies [119,120]. The
mouse bone marrow micronucleus test gave positive
results after repeated application [4,119]. However, single
exposure was used in the Muta™mouse assay [120]. Stud-
ies on other in vivo genotoxicity endpoints have shown
almost negative results after single exposure but genotoxic
activity after repeated application, for example in the
mouse bone marrow micronucleus assay [4]. Positive
results might be expected in the Muta™mouse assay using
another experimental design since other in vivo as well as
in vitro test systems revealed gene mutagenic effects.
Methyl methanesulfonate
Only weak mutagenic effects in the liver but no effects in
bone marrow were observed in the Muta™mouse [18,124]
and negative results in the Big Blue®  mouse [111-
113,126]. In the mouse bone marrow micronucleus test
this carcinogenic substance induced chromosome aberra-
tion [1,127]; other in vitro and in vivo assays clearly sup-
ported the clastogenic activity [121,122]. There is
evidence that the chromosome mutagenic activity is
detectable at much lower doses than the gene mutagenic
activity. Tinwell et al. (1998) [18] have shown on
Muta™mice a weak gene mutagenic effect in the liver but
no effect in the bone marrow. The same dose induced in
these animals a significant increase in bone marrow
micronuclei indicating clear clastogenic activity. Overall,
methyl methanesulfonate is more clastogenic than gene
mutagenic.
Mitomycin C
A very similar situation is given with mitomycin C. No
mutagenic activity was observed in the Muta™mouse assay
in liver and bone marrow after single injection but the
same dose induced chromosome aberrations in the bone
marrow of the same mice [142]. The mouse bone marrow
micronucleus test [1,47] and all in vivo and in vitro assays
on the endpoint chromosome aberration revealed clearly
positive results [139-141].
N-Nitrosodiethylamine
The main target organ in systemic carcinogenesis is the
liver [146-148]. As expected, mutagenic effects were
detected in the liver of the Muta™mouse, but none in the
bone marrow [104,106,149,150]. The same mice showed
also no micronuclei at these dose levels [104]. Conse-
quently, the mouse bone marrow micronucleus test gave
negative results indicating that this is not a target organ of
genotoxicity. However, there is also evidence that this sub-
stance shows more gene mutagenic activity than clas-
togenic activity because other in vivo studies gave no clear
indication for chromosome aberration (see Additional
file 1).
N-Nitrosodi-N-propylamine
There is evidence that this substance shows more gene
than chromosome mutagenic activity. Beside local carci-
nogenic effects in carcinogenicity studies on mice and rats
systemic effects were located in the liver (mouse and rats)
and in bone marrow (rat) [160-163]. Several target organs
were detected in the Muta™mouse assay including liver
and bone marrow [164]. But no chromosome mutagenic
activity was recorded in the mouse bone marrow micro-
nucleus test [4]. Further in vivo data on this endpoint are
not available (see Additional file 1).
Phenobarbital
Liver tumours were detected in carcinogenicity studies on
mice and rats [165-167]. In the Muta™mouse assay no
mutagenic activity was observed although the liver weight
of the treated mice increased indicating systemic effects in
this organ [149,168]. Two studies are available on the Big
Blue® mouse, one gave negative [16] and the other weak
positive results [169]. Taken together the results in trans-
genic mice are inconclusive which is in accord with the
mouse bone marrow nucleus test (inconclusive results).
Inconclusive (in vitro) or negative results were obtained in
other studies on clastogenicity or other endpoints of gen-
otoxicity (see Additional file 1).Journal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3
Page 5 of 14
(page number not for citation purposes)
Overall, there is no clear indication of gene or chromo-
some mutagenic activity in transgenic mouse assays or
other genotoxic tests systems. However, genotoxic mecha-
nisms in carcinogenicity cannot be excluded.
β-Propiolactone
This is an alkylating substance with predominantly local
carcinogenic effects[175,176]. In the Muta™mouse assay
[131] local effects in the stomach were observed in gavage
studies plus systemic effects in the liver, but no mutagenic
activity was seen in bone marrow of the Muta™mouse
[131]. As expected, no increased incidence in micronuclei
was detected in the bone marrow of treated mice [1,4]
although clastogenic effects were observed in in vitro stud-
ies, in insects and plants (see Additional file 1) indicating
chromosomal aberration after direct contact with this
alkylating substance.
Trichloroethylene
This substance gave clearly positive results in different car-
cinogenicity studies on mice [186]. Although the target
organs of carcinogenicity (including bone marrow) were
investigated in the Muta™mouse assay, no mutagenic
activity was noted [187]. The positive results in the mouse
bone marrow micronucleus test are contradictory to other
in vivo studies on clastogenicity. However, a further (sim-
ple) reason for the negative results in the Muta™mouse
assay might be that the MTD was not reached [187]. Over-
all, further discussion on the mechanisms of carcinogenic-
ity is necessary.
Tris(2,3-dibromopropyl)phosphate
This might be a further example for a substance where
genotoxic effects are not related to the target organ bone
marrow but induce systemic effects in others. The target
organ in oral carcinogenicity studies on mice and rats was
the kidney, in mice systemic carcinogenic effects were also
seen in lung and liver [188-190]. In the Big Blue® mouse
assay, mutagenic activity was detected in the kidney in
gavage studies[46,191]. The mouse bone marrow micro-
nucleus assay (i.p. injection)[4] as well as cytogenetic
studies on rats and mice were negative [188-190].
Substance without data on carcinogenicity in mice and 
differing results in the micronucleus test and transgenic 
mouse assay
4-Acetylaminofluorene
This substance showed mutagenic activity in the
Muta™mouse assay [18] but inconclusive results in the
mouse bone marrow micronucleus test [2]. No data on
carcinogenicity are available on 4-acetylaminofluorene.
However, data on two in vitro mammalian test systems
indicated gene mutagenic activity [17] supporting results
in the transgenic assay.
Substances without carcinogenic effects in mice and 
differing results in the micronucleus test and transgenic 
mouse assay
Bromomethane
No increased tumour incidences were observed in mice as
well as in re-evaluated studies on rats [58,59]. Negative
results were obtained also in the examined organs includ-
ing liver and bone marrow in the Muta™mouse assay.
However, DNA methylation in the liver was observed in
the same assay even at lower dose levels [60] indicating
differences in the sensitivity of these two genotoxic end-
points. The mouse micronucleus test revealed chromo-
some mutagenic activity [61] although results of other in
vivo tests are equivocal (see Additional file 1).
2,6-Diaminotoluene
No carcinogenic effects were seen in a valid long-term
study on mice and rats [85]. In the Big Blue® mouse no
mutagenic activity was induced [82,84]. However, only
the liver was examined and the assays had some limita-
tions (one dose tested, MTD possibly not reached). The
mouse micronucleus test revealed chromosome aberra-
tions [3,47] as well as the available in vitro studies but no
clastogenic activity was detected in a cytogenetic study on
rodents (see Additional file 1).
Substances with carcinogenic effects in mice but 
nongenotoxic mechanisms are presumed
Chloroform (German MAK Classification 4 = substances with 
carcinogen effects where the genotoxic effects are absent or only 
play an insignificant role)
Liver tumours were induced in B6C3F1 mice [72], how-
ever no mutagenic effects were detected in the liver of Big
Blue® mice of the same strain in a valid assay [74]. Accord-
ingly, no increased incidence in micronuclei were
observed in the bone marrow of mice [1,47] and no clas-
togenicity in in vitro studies (see Additional file 1). In con-
trast, rats showed clastogenic activity in the kidney, but
only at toxic dose levels [73].
Di-(2-ethylhexyl)phthalate (German MAK Classification 4)
This substance induced liver tumours in mice and rats
[86]. No increased mutation frequency was seen in the
liver of the Big Blue® mouse [16] (limited validity, MTD
presumably not reached) and no chromosome aberration
in the mouse micronucleus test [4]. The majority of in vitro
and in vivo tests revealed also negative results with di-(2-
ethylhexyl)phthalate (see Additional file 1).
Tetrachloromethane (German MAK Classification 4)
An increased incidence of liver tumours were induced in
mice and in rats [185]. However, no mutagenic activity in
the liver was reported in a Muta™mouse assay although
the organ weight increased in the same mice indicating
some hepatocellular regeneration [168]. No chromosomeJournal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3
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aberration was induced in the mouse bone marrow micro-
nucleus test [4]. Also other studies on this endpoint and
the majority studies on other endpoint of genotoxicity
revealed negative results (see Additional file 1).
Discussion on the comparison of both assays
Most carcinogens in Additional file 1 are positive in trans-
genic mouse assays and in the mouse bone marrow micro-
nucleus test although different endpoints are studied. This
indicates coincidence in both test systems and/or effects
of the test substance on different genotoxic endpoints.
However, there are several substances (see above for
example ortho-anisidine) whose mutagenic (and carcino-
genic) potential could not be demonstrated with the
mouse bone marrow micronucleus test but with the trans-
genic mouse assay. This might be due to the fact that the
micronucleus test is restricted to the bone marrow as tar-
get organ. In contrast, all organs can be examined in trans-
genic mouse assay for mutagenic activity without any
restrictions.
A special subgroup of substances should also be men-
tioned: substances with predominantly local mutagenic/
carcinogenic effects and less systemic direction of effects.
For these substances the mouse bone marrow micronu-
cleus test is an unsuitable test system.
Beside the restrictions on the target organ there is also
given the possibility that a substance induces predomi-
nantly gene mutations and not or less chromosome aber-
rations at the same dose level. The example N-nitrosodi-
N-propylamine has shown positive results in different tar-
get organs including the bone marrow using the trans-
genic mouse assay but negative results were shown in the
mouse micronucleus test.
On the other hand there are also substances for which the
transgenic mouse assay is an unsuitable test system. The
examples methylmethanesulfonate and mitomycin C
have shown that chromosome aberration and not gene
mutation is the predominant endpoint at the correspond-
ing dose level in vivo. These genotoxic effects are not easily
detectable with the transgenic mouse assay which is
restricted to the detection of small deletion and insertions
in the DNA. However, the negative Muta™mouse assay on
mitomycin C has some limitations in the validity of the
test system. With increased dose levels (MTD reached)
and/or repeated application also gene mutagenic effects
might be detected in the transgenic mouse assay.
Interestingly, substances with carcinogenic effects induced
by nongenotoxic mechanisms gave mainly correct nega-
tive results in both test systems although the protocols for
the transgenic mouse assays were not optimised except for
chloroform.
Predictability of the transgenic animal assays and the 
mouse bone marrow micronucleus test for carcinogenicity
The sensitivity, specificity and predictive values to cancer
for the Muta™mouse assay and the Big Blue® mouse assay
combined, and the mouse bone marrow micronucleus
test are documented in Table 1. In the present study data
on 38 substances were available concerning carcinogenic-
ity in mice and mutagenic effects in transgenic mice as
well as mutagenic effects in the mouse bone marrow
micronucleus test (Additional file 1). The two substances
with inconclusive results in the mouse bone marrow
micronucleus assay (phenobarbital & acrylamide) were
not included in the final calculation data and in the com-
Table 1: Characteristics of the Muta™mouse assay and the Big Blue® mouse assay for predicting mouse carcinogenicity in comparison 
with the micronucleus test
Term# Calculation for the mouse bone marrow 
micronucleus test
Calculation for Muta™mouse and/or Big Blue® 
mouse combined *
Sensitivity 68% (23/34) 82% (28/34)
Specificity 0% (0/2) 100% (2/2)
Positive predictability 92% (23/25) 100% (28/28)
Negative predictability 0% (0/11) 25% (2/8)
Overall accuracy 64% (23/36) 83% (30/36)
# Sensitivity = % of carcinogens with a positive result in the specified test system (STS)
Specificity = % of noncarcinogens with a negative result in STS
Positive predictability = % of positive results in the STS that are carcinogen
Negative predictability = % of negative results in the STS that are noncarcinogens
Overall accuracy = % of chemicals tested where STS results agree with the carcinogenicity results
Carcinogens with genetoxic and nongenotoxic mechanisms were considered but not noncarcinogenic substances; only data on mice were used
Weak positive results in transgenic mouse assays judged as positive.
*: judged as positive in transgenic assays if positive in one of the two test systemsJournal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3
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parison of the micronucleus test versus the transgenic
mouse assay.
Although the data pool in this document is not sufficient
for a comprehensive comparison (low number of exam-
ples, especially for specificity and negative predictability;
limitations of most transgenic mouse assays with negative
results) some differences were apparent between the two
test systems.
The overall accuracy of the micronucleus test is lower than
that of the transgenic mouse assays. This is mainly due to
11 negative results in the micronucleus test system (nega-
tive in the micronucleus test but positive in carcinogenic-
ity studies) influencing the terms sensitivity and negative
predictability. Three of these negative results in the micro-
nucleus test are obtained with carcinogenic substances
[chloroform, di-(2-ethylhexyl)phthalate, and tetrachlo-
romethane] for which carcinogenic effects are considered
to be of a nongenotoxic mechanism. However, chloro-
form, di-(2-ethylhexyl)phthalate and tetrachloromethane
gave negative results in transgenic mice, so the compari-
son of both test system is not essentially affected and the
evaluation „nongenotoxic“ supported. For the other 8
substances out of these 11 with false negative results in the
micronucleus test these results are explainable (see
above): Ortho-anisidine (mutagenic/carcinogenic effects
are restricted to the bladder), IQ (bone marrow presuma-
bly not target organ of genotoxicity in mice and more gene
mutagenic than clastogenic), asbestos (local genotoxic/
carcinogenic effects in the lung), 2,4-diaminotoluene (tar-
get organ liver, presumably not bone marrow), N-nitroso-
diethylamine (target organ liver, more gene mutagenic
than clastogenic), N-nitroso-N-propylamine (presumably
more gene mutagenic than clastogenic), beta-propiolac-
tone (mainly local effects and less systemic effects [in
bone marrow]), tris(2,3-dibromopropyl)phosphate (sys-
temic effects not related to the bone marrow).
The term negative predictability is also low in the trans-
genic mouse assay due to false negative results on six car-
cinogenic substances; for three of them, hydrazine,
mitomycin C, and tetrachloroethylene (detailed treatise
in section „direct comparison“, see above) genotoxic
mechanisms are presumed. For hydrazine (no repeated
application) and tetrachloroethylene (MTD not reached)
limitations on the experimentel design might be the rea-
son for the negative results. Mitomycin C is clearly more
clastogenic than gene mutagenic, and the transgenic
mouse with lacI and lacZ is possibly an unsuitable test sys-
tem. For 3 out of the 6 substances the carcinogenic effects
in mice were attributed to nongenotoxic mechanisms:
chloroform, di-(2-ethylhexyl)phthalate and tetrachlo-
romethane (see also above), all gave negative results in
transgenic mice.
Only two substances with negative results in long-term
carcinogenicity studies are available in the data pool: bro-
momethane and 2,6-diaminotoluene. Both gave correct
negative results in the transgenic mouse assay (although
of limited validity) but false positive results in the micro-
nucleus test (see term specificity).
Generally, the differences between the two test systems
might be due to the fact that 1) unequal genotoxic end-
points are investigated (chromosome aberration in the
micronucleus test versus gene mutation in the transgenic
mouse assay), 2) organotrophy of genotoxic effects (espe-
cially bone marrow not target organ) might play an essen-
tial role and 3) transgenic rodent assay conditions in the
different systems may not be optimal for mutation
detection.
Advantages and disadvantages of both test systems
A comparison of the transgenic mouse assays with the
mouse bone marrow micronucleus test is limited by the
fact that different genotoxic endpoints are studied in these
two systems. In transgenic mouse assays, point mutations
and small insertions and deletions are detected whereas in
the mouse bone marrow assay, chromosome breakage
leading to light microscopically visible micronuclei result-
ing from chromosome fragment or micronuclei origi-
nated from whole chromosomes are investigated.
Sensitivity of the test system
In comparison to other test systems in genotoxicity testing
using endogenous target structures the spontaneous
mutant frequency in the transgenic mouse assay is rela-
tively high. This might be related to the fact that bacterial
DNA is the target gene (high methylation rate) or the
transgene is silent and no transcription related repair
occurs like in endogenous genes which are more effi-
ciently repaired [9]. In the mouse bone marrow micronu-
cleus test the spontaneous rate of micronuclei is low
ranging between 1–3 PCEs with micronuclei per 1000
PCEs. However, frequency of chromosome aberrations is
not directly comparable with a gene mutantion frequency.
Comparing the target organs and cells at risk at the time of
exposure, the mouse micronucleus test is restricted to one
target organ, the bone marrow, especially to the erythrob-
lasts. This limitation is not given in transgenic mouse
assays: target cells are cells in all organs [195].
Considerations of animal welfare
Both test systems are similar in the number of animals
used for a valid test. The minimal number of mice needed
in the mouse bone marrow assay is 25 per gender (3 dose
levels, vehicle control, positive control; 5 mice per group)
using a treatment schedule with 2 or more applications at
24 h intervals and sampling 18–24 h following the finalJournal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3
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treatment. In the limit test (for a test substance of low tox-
icity) only one dose level of 2000 mg/kg bw is necessary
(OECD guideline 474, [6]).
In transgenic mutation assays ca. 20 animals (3 dose
groups and 1 concurrent vehicle control group in labora-
tories which already established this test system) are rec-
ommended per species and gender [196,197]. In terms of
animal welfare, it is also desired to merge more than one
in vivo genotoxicity assay such as transgenic mouse assay
and micronucleus assay using the same animals for both
assays.
Cost effectiveness
Due to the simplicity of the mouse bone marrow micro-
nucleus assay and the use of systems for automated anal-
ysis, this test is less expensive than the transgenic mouse
assay.
A comparison both test systems is presented in Table 2.
Conclusions
In a comparison of the tests available to genetic toxicolo-
gists, the results from studies on substances which had
been tested in transgenic mutagenicity assays Big Blue®
mouse and the Muta™mouse were compared with those
from the more traditional mouse bone marrow micronu-
cleus test. The transgenic animal mutation assay, which is
Table 2: Comparison of the mouse bone micronucleus assay with transgenic mouse models (Muta™mouse and the Big Blue® assay)
Mouse bone marrow micronucleus test 
[1,2]
Transgenic mouse mutation assay [9,195]
Type of endpoint Detects light microscopically visible 
micronuclei resulting from whole 
chromosomes or chromosome fragments 
following chromosome breakage
Detects 1) gene mutation, 2) small deletions or 
insertions
Regulatory use Widespread acceptance (OECD guideline 
established since 1983)
Not widely used by the industry in 
toxicological screening; OECD guideline in 
preparation
Background mutation rate Spontaneous incidence of micronuclei is low 
(ca. 0.3%) and almost uniform
High spontaneous rate of mutations comparing 
with other mutation assays
Negative predictivity low negative predictivity for cancer Low negative predictivity for cancer
Implementation Simplicity of the test system; easily recognised 
end-point
Higher Complexity of the test system (target 
cells in mice and expression of mutagenic 
effects in bacteria; vector system needed)
Toxicokinetics and metabolism Restrictions in toxicokinetics: test substance or 
the toxic metabolites may not reach the bone 
marrow but other target organs
No restrictions after absorption and 
distribution of the test substance
Target tissue Restricted to erythroblasts in the bone 
marrow
No tissue restriction; analysis of mutagenic 
potency in different organs; measurement of 
organotrophic effects
Dependency of effects on application 
route
Only systemic effects can be detected Systemic as well as local mutagenic effects can 
be detected
Number of animals 5 animals per gender per dose recommended 5 animals per gender per dose recommended
Restrictions on the used model Also some recommendations are given in 
OECD guideline 474, no limitation concerning 
species, strain, gender, age of animals, exposure 
duration
Limitations: Muta™mouse assay only 1 species 
& 1 strain; Big Blue® 2 species (mouse and rat) 
but 1 (rat) or 2 strains (mouse); no limitations 
on other parameters
Costs Less expensive due to the simplicity of the test 
system
More expensive test system
Molecular mechanism Mechanisms of the induction of micronuclei 
originating from chromosome fragments could 
not be resolved
Detection of the "molecular signature" of a 
particular mutagenic substance by DNA 
sequence analysis with standardised methods
Parallel examination of different genetic 
endpoints
Combination with other genotoxic endpoints is 
not recommended but possible if results of the 
micronucleus test are not influenced and vice 
versa
The transgenic mouse assay can be combined 
with other in vivo genotoxic endpoints in the 
same animal: micronuclei, chromosomal 
aberration, UDS, SCE
Type of mutational target In situ end point Target genes are integrated parts of foreign 
DNA and consequently no "normal" mutational 
target, no expression
UDS: unscheduled DNA synthesis; SCE: sister chromatid exchange.Journal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3
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not yet used in toxicological screening, is not directly
comparable with the micronucleus test, because different
genetic endpoints are examined: chromosome aberration
versus gene mutation. However, from the 39 substances,
the majority gave the same positive or negative result in
both test systems. The substances where differences
occurred were discussed in more detail. The advantages
and disadvantages of the transgenic Big Blue® mouse and
the Muta™Mouse transgenic model compared to the
micronucleus test were discussed and both systems were
found to have a place in mutagenicity testing and to sup-
plement each other. The transgenic animal assay has,
however, some distinct advantages over the micronucleus
test in that it is not restricted to one target organ and
detects systemic as well as local mutagenic effects.
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